Home > Healthcare & Medical Devices > HPV Testing and Pap Test Market
HPV Testing and Pap Test Market Size is expected to grow at a notable CAGR from 2022 to 2028 on account of the surging technological advancements in diagnostics. The globally increasing count of chronic diseases, including vaginal and cervical cancer, have stirred the rise in the number of screening programs.
While HPV (human papillomavirus) testing is used for screening human papillomavirus in the cervix that results in cervical cancer, pap test (Papanicolaou test) is an effective screening measure to predict if cervical cells are abnormal or normal. However, the low reliability and inaccuracy of the pap test may pose a barrier to the industry growth in the ensuing years.
In terms of test type, the market share from HPV testing will increase with the growing consumer awareness and rising penetration in cervical cancer screening. This testing procedure has the ability for self-collection and can predict women who are at high risk for future disease. It is increasingly preferred over Pap smears to offer equivalent or higher sensitivity, and limited technician skills. The growing consistency and effectiveness of HPV primary tests will also push the market growth.
With respect to application, the HPV testing and pap test industry revenue from the cervical cancer screening segment will expand owing to the growing consumer awareness on early diagnosis and treatment of cancer. The rising instances of cervical cancer across the world and the increasing government support to limit the disease burden will fuel the market progression.
Based on end-use, the adoption of HPV testing and pap test procedures in hospitals will rise with the expanding patient volumes in these facilities. The higher availability of advanced equipment and the presence of trained staff along with the thriving need for comparatively low-cost diagnostic tests has resulted in growing healthcare spending. The influx of various advanced technologies and the provision of well-equipped assays and test kits for the detection of cervical and vaginal cancer in public and private hospitals will favor the market growth.
North America is anticipated to be a major revenue ground for the HPV testing and pap test industry through 2028. This is mainly due to the increasing instances of screening procedures on account of the surging number of cervical cancer cases in the region. According to the American Cancer Society, over 14,480 new cases of invasive cervical cancer are estimated to be diagnosed in the U.S. in 2021. The presence of favorable government policies along with the higher amount of funding & grants has resulted in the growing emphasis on breast and cervical cancer screening. The influx of HPV primary tests is another prominent driver for the market growth.
Roche Diagnostics, Quest Diagnostics, Arbor Vita Corporation, Becton Dickinson & Company, Femasys, Hologic, Onco Health Corporation, Abbott Laboratories, Seegene, and Qiagen are leading players in the HPV testing and pap test industry.
These firms are constantly adopting strategic measures, such as partnerships, acquisitions, and investments, to reinforce their global footprint. They are also working on innovations and product approvals from regulatory authorities to achieve competitive advantages.
For instance, in April 2020, Roche announced the U.S. FDA (Food and Drug Administration) approval for cobas®, its HPV test used on fully automated and high throughput cobas® 6800/8800 systems. The novel test identifies women prone to cervical cancer as it detects the presence of high-risk HPV (human papillomavirus) DNA in cervical samples.
In response to the COVID-19 pandemic, the HPV testing and pap test industry witnessed sluggish growth due to the challenges posed on existing laboratory services and the performance of HPV-based screening given the escalating SARS-CoV-2 admissions. Shortage of staff and the potential delays in innovations in primary HPV testing led to disruptions in cancer screening services, negatively impeding the market expansion during the outbreak.
Market, by Test Type
Market, by Application
Market, by End-use
The above information is provided for the following regions and countries: